PURPOSE: Biochemical control (bNED), disease-specific survival (DSS), overall survival (OS), and late gastrointestinal (GI) and urogenital (UG) side effects (EORTC/RTOG) of patients with long-term follow-up were evaluated. PATIENTS AND METHODS: Three-dimensional radiotherapy up to 66 Gy with/without additional hormonal therapy was performed in 154 prostate cancer (T1-3 N0 M0) patients. According to T-stage, pretreatment prostate-specific antigen (PSA) and grading, patients were divided into a low-, intermediate-, and high-risk group. The 5-, 8-, and 10-year actuarial rates of bNED, DSS and OS and late side effects were calculated. RESULTS: Median follow-up was 80 months. Additional hormonal therapy was given in 57% of patients. Distribution concerning risk groups (low, intermediate, high) showed 15%, 49%, and 36% of patients, respectively. bNED 5-, 8-, and 10-year actuarial rates were 46%, 44%, and 44%. DSS 5-, 8- and 10-year rates amounted to 96%, 90%, and 82%. OS 5-, 8- and 10-year rates were 81%, 64%, and 56%. In uni- and multivariate analysis, only pretreatment PSA (<10 vs. >or=10 ng/ml; p<0.05) and PSA nadir (<0.5 vs. >or=0.5 ng/ml; p<0.0001) affected bNED significantly. Age, risk group, T-stage, grading, and hormonal therapy had no significant influence on bNED, DSS, and OS. Rates of late GI and UG side effects grade>or=2 at 5 years were 17% and 15%. CONCLUSION: Current dose escalation studies with better bNED rates may be able to further increase long-term clinical outcome.
PURPOSE: Biochemical control (bNED), disease-specific survival (DSS), overall survival (OS), and late gastrointestinal (GI) and urogenital (UG) side effects (EORTC/RTOG) of patients with long-term follow-up were evaluated. PATIENTS AND METHODS: Three-dimensional radiotherapy up to 66 Gy with/without additional hormonal therapy was performed in 154 prostate cancer (T1-3 N0 M0) patients. According to T-stage, pretreatment prostate-specific antigen (PSA) and grading, patients were divided into a low-, intermediate-, and high-risk group. The 5-, 8-, and 10-year actuarial rates of bNED, DSS and OS and late side effects were calculated. RESULTS: Median follow-up was 80 months. Additional hormonal therapy was given in 57% of patients. Distribution concerning risk groups (low, intermediate, high) showed 15%, 49%, and 36% of patients, respectively. bNED 5-, 8-, and 10-year actuarial rates were 46%, 44%, and 44%. DSS 5-, 8- and 10-year rates amounted to 96%, 90%, and 82%. OS 5-, 8- and 10-year rates were 81%, 64%, and 56%. In uni- and multivariate analysis, only pretreatment PSA (<10 vs. >or=10 ng/ml; p<0.05) and PSA nadir (<0.5 vs. >or=0.5 ng/ml; p<0.0001) affected bNED significantly. Age, risk group, T-stage, grading, and hormonal therapy had no significant influence on bNED, DSS, and OS. Rates of late GI and UG side effects grade>or=2 at 5 years were 17% and 15%. CONCLUSION: Current dose escalation studies with better bNED rates may be able to further increase long-term clinical outcome.
Authors: Martin Dolezel; Karel Odrazka; Milan Zouhar; Miloslava Vaculikova; Jana Sefrova; Jan Jansa; Petr Paluska; Tereza Kohlova; Jaroslav Vanasek; Josef Kovarik Journal: Strahlenther Onkol Date: 2015-01-15 Impact factor: 3.621
Authors: Martin Dolezel; Karel Odrazka; Miloslava Vaculikova; Jaroslav Vanasek; Jana Sefrova; Petr Paluska; Milan Zouhar; Jan Jansa; Zuzana Macingova; Lida Jarosova; Milos Brodak; Petr Moravek; Igor Hartmann Journal: Strahlenther Onkol Date: 2010-03-26 Impact factor: 3.621
Authors: Andrea Hille; Markus K A Herrmann; Tereza Kertesz; Hans Christiansen; Robert M Hermann; Olivier Pradier; Heinz Schmidberger; Clemens-F Hess Journal: Strahlenther Onkol Date: 2008-12-24 Impact factor: 3.621